The screening of 1933 HER2-negative metastatic breast cancer patients for HER2-positive CTCs revealed that 174 (15%) patients out of 1159 CTC-positive patients showed HER2-positive CTCs. This evidence concerns the gene ERBB2 and breast carcinoma.